Murphy & Mullick Capital Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Murphy & Mullick Capital Management’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.99K	Hold	275	–	–	0.01%	496
2025 Q4	$7.2K	Hold	275	–	–	0.01%	514
2025 Q3	$6.93K	Hold	275	–	–	0.01%	509
2025 Q2	$5.64K	Hold	275	–	–	﹤0.01%	508
2025 Q1	$5.63K	Hold	275	–	–	0.01%	496
2024 Q4	$6.22K	Buy	+275	New	+$6.6K	0.01%	488

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Murphy & Mullick Capital Management's IDNA Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its iShares Genomics Immunology and Healthcare ETF (IDNA) position steady in Q1 2026 at 275 shares worth $7.99K. The position accounts for 0.01% of the portfolio, ranked #496.

Murphy & Mullick Capital Management first reported a position in IDNA in Q4 2024 and has held it in 6 quarters since. 60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Murphy & Mullick Capital Management held 275 shares of iShares Genomics Immunology and Healthcare ETF worth $7.99K as of Q1 2026.
Murphy & Mullick Capital Management left its iShares Genomics Immunology and Healthcare ETF share count unchanged in Q1 2026.
iShares Genomics Immunology and Healthcare ETF made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #496 holding.
Murphy & Mullick Capital Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2024 and has held it in 6 quarters since.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.